OptiBio is a South Korean healthcare company focused on fluorescence immunoassay (FIA) solutions. In 2020, OptiBio was selected by a research fund sponsored by the Bill & Melinda Gates Foundation for its unique and dedicated approach to immunoassay.
OptiBio's competitive advantage stems from its strong foundation of experts, each specialized in fields crucial for product development. Our R&D is divided into 3 different teams of scientists and engineers dedicated to the independent development of diagnostic markers, test kits, and analyzers.
OptiBio will continue to create, improve, and innovate world-class diagnostic solutions in the field of fluorescence immunoassay and point-of-care testing (POCT). Through this, we aim to ultimately transform medical diagnosis into a universally available right.